Considering the chronically elevated STAT1 activation status of MT/Shc313F/313F tumours, we reasoned that they could be sensitized to alternative immunotherapeutic strategies that favour re-activation of antigen-specific tumour immunity. The gene discussed is STAT1; the disease is neoplasm.